- Board of Directors
- Committee Charters
- Code of Conduct
- Ethics and Compliance Hotline
- Board Diversity Matrix
John P. Brancaccio
Director
John P. Brancaccio, a retired C.P.A., has served as a Director of our company since May 2013. Since April 2004, Mr. Brancaccio has been the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies. From May 2002 until March 2004, Mr. Brancaccio was the Chief Financial Officer of Memory Pharmaceuticals Corp., a biotechnology company. From 2000 to 2002, Mr. Brancaccio was the Chief Financial Officer/Chief Operating Officer of Eline Group, an entertainment and media company. Learn More >>
Timothy M. Block, Ph.D.
Director
Timothy M. Block, Ph.D., has served as a Director of our company since October 2013. Dr. Block currently serves as Co-founder and President of the Hepatitis B Foundation (HBF) and its Baruch S. Blumberg Institute (formerly called the Institute for Hepatitis and Virus Research), the nation’s leading nonprofit organizations dedicated to improving the lives of those affected worldwide through research, education and patient advocacy. He also serves as President and CEO of the Pennsylvania (PA) Biotechnology Center. Learn More >>
Kaouthar Lbiati, M.D.
Director
Dr. Lbiati is a multi-functional executive with a combination of scientific, business, finance, global health policy, and health economics skills. She is currently Vice President, Strategy & Corporate Development at Cytovia Therapeutics, a biopharmaceutical company specializing in immuno-oncology and cell therapies. Dr. Lbiati previously served in global and regional leadership roles at Amgen, Glaxo Smith Kline, and Sanofi, where she supported the registration, launch and/or indication extension and reimbursement of innovative cancer drugs including Blincyto®, Jevtana® and Votrient®. Learn more >>
Michael Purcell
Director
Mr. Purcell has more than 37 years of professional experience with Deloitte & Touche LLP, serving as a consultant from 2015 to 2017 and an Audit Partner from 1979 until 2015. Mr. Purcell also currently serves as a financial advisor to several emerging growth companies. Mr. Purcell is a certified public accountant and has provided assurance and advisory services to public and private enterprise clients of all sizes over the course of his career. Learn more >>
Hepion Pharmaceuticals, Inc.’s Board of Directors approved the Anonymous Ethics and Compliance Hotline on December 9, 2015 which is effective as of January 1, 2016.
Hepion Pharmaceuticals, Inc. promotes a trustworthy and honest work environment and reinforces the vision of these ethics within the organization. Hepion Pharmaceuticals, Inc. will not tolerate any wrongdoing or impropriety and takes allegations of fraud, waste and abuse very seriously. Hepion Pharmaceuticals, Inc. is committed to achieving the highest possible standards of ethics and behavior in its corporate governance and workplace.
It is Hepion Pharmaceuticals, Inc.’s policy to comply with all applicable laws and to protect employees against unlawful discrimination or retaliation by their employer as a result of their lawfully reporting information regarding, or their participation in, investigations involving violations by Hepion Pharmaceuticals, Inc. or its agents of federal or state law.
In order to facilitate the reporting of complaints, Hepion Pharmaceuticals, Inc. has established this whistleblower hotline through Lighthouse Services, Inc. If you have a matter that you wish to bring to our attention, please select one of the following methods to report your complaints or concerns.
- English speaking USA and Canada: 855-850-0005
- Spanish speaking USA and Canada: 800-216-1288
- Spanish speaking Mexico: 01-800-681-5340
- French speaking Canada: 855-725-0002
- Website: www.lighthouse-services.com/hepionpharma
- E-mail: reports@lighthouse-services.com (must include company name with report)
- Fax: (215) 689-3885 (must include company name with report)
Lighthouse toll free number and other methods of reporting are available 24 hours a day, 7 days a week. Complaints should be as detailed and complete as possible and include references to any supporting documentation in order to allow effective and efficient investigation thereof. Hepion Pharmaceuticals Inc.’s Audit Committee will oversee investigation and treatment of employee concerns collected. Unless you choose to provide it, personally identifiable information remains confidential.
